Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor

18 Jan 2019

Abstract excerpt

Homoharringtonine (HHT), a known protein synthesis inhibitor, has an anti-myeloid leukemia effect and potentiates the therapeutic efficacy of anthracycline/cytarabine induction regimens for acute myelogenous leukemia (AML) with favorable and intermediate prognoses, especially in the t(8;21) subtype. Here we provide evidence showing that HHT inhibits the activity of leukemia-initiating cells (Lin − /Sca-1 − /c-kit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Retinoids in leukemia and cellular processes
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30659143
DOI: 10.1073/pnas.1818539116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factorPMID 30659143Read ↗

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmCSemantic proximity Read ↗

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.Semantic proximity Read ↗

Homoharringtonine binds to and increases myosin‐9 in myeloid leukaemiaSemantic proximity Read ↗

XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment.Semantic proximity Read ↗

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.Semantic proximity Read ↗

Network pharmacology of triptolide in cancer cells: implications for transcription factor bindingSemantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.Semantic proximity Read ↗

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.Semantic proximity Read ↗

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.Semantic proximity Read ↗

Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoidsSemantic proximity Read ↗

Bortezomib synergizes with homoharringtonine in FLT3-ITD-relapsed/refractory acute myeloid leukemia by inducing FLT3-ITD protein degradation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.